Tissue Engineered - Skin Substitutes - Medical Devices Pipeline Assessment, 2017

  • ID: 4370678
  • Drug Pipelines
  • 157 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Adept Medical Ltd
  • AGAM Biological Products
  • Kerecis ehf
  • Lattice Biologics Ltd
  • MiMedx Group Inc
  • Organogenesis Inc
  • MORE
Tissue Engineered - Skin Substitutes - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Tissue Engineered - Skin Substitutes - Medical Devices Pipeline Assessment, 2017" provides an overview of Tissue Engineered - Skin Substitutes currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Tissue Engineered - Skin Substitutes pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Tissue Engineered - Skin Substitutes under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Tissue Engineered - Skin Substitutes and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Tissue Engineered - Skin Substitutes under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adept Medical Ltd
  • AGAM Biological Products
  • Kerecis ehf
  • Lattice Biologics Ltd
  • MiMedx Group Inc
  • Organogenesis Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Introduction
2.1 Tissue Engineered - Skin Substitutes Overview

3. Products under Development
3.1 Tissue Engineered - Skin Substitutes - Pipeline Products by Stage of Development
3.2 Tissue Engineered - Skin Substitutes - Pipeline Products by Segment
3.3 Tissue Engineered - Skin Substitutes - Pipeline Products by Territory
3.4 Tissue Engineered - Skin Substitutes - Pipeline Products by Regulatory Path
3.5 Tissue Engineered - Skin Substitutes - Pipeline Products by Estimated Approval Date
3.6 Tissue Engineered - Skin Substitutes - Ongoing Clinical Trials

4. Tissue Engineered - Skin Substitutes - Pipeline Products under Development by Companies
4.1 Tissue Engineered - Skin Substitutes Companies - Pipeline Products by Stage of Development
4.2 Tissue Engineered - Skin Substitutes - Pipeline Products by Stage of Development

5. Tissue Engineered - Skin Substitutes Companies and Product Overview
5.1 Adept Medical Ltd Company Overview
5.1.1 Adept Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.2 AGAM Biological Products Company Overview
5.2.1 AGAM Biological Products Pipeline Products & Ongoing Clinical Trials Overview
5.3 Agenta Biotechnologies Inc Company Overview
5.3.1 Agenta Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Kerecis ehf Company Overview
5.4.1 Kerecis ehf Pipeline Products & Ongoing Clinical Trials Overview
5.5 Lattice Biologics Ltd Company Overview
5.5.1 Lattice Biologics Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.6 Mallinckrodt Pharmaceuticals Company Overview
5.6.1 Mallinckrodt Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview
5.7 MiMedx Group Inc Company Overview
5.7.1 MiMedx Group Inc Pipeline Products & Ongoing Clinical Trials Overview
5.8 Organogenesis Inc Company Overview
5.8.1 Organogenesis Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 Smith & Nephew Plc Company Overview
5.9.1 Smith & Nephew Plc Pipeline Products & Ongoing Clinical Trials Overview
5.10 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview
5.10.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview
5.11 Stratatech Corp Company Overview
5.11.1 Stratatech Corp Pipeline Products & Ongoing Clinical Trials Overview
5.12 Tel Aviv University Company Overview
5.12.1 Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview
5.13 Tissue Regenix Ltd Company Overview
5.13.1 Tissue Regenix Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.14 Vericel Corp Company Overview
5.14.1 Vericel Corp Pipeline Products & Ongoing Clinical Trials Overview
5.15 Worcester Polytechnic Institute Company Overview
5.15.1 Worcester Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview

6. Tissue Engineered - Skin Substitutes- Recent Developments
6.1 Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results
6.2 Jul 18, 2017: U.S. FDA Designates Mallinckrodt's StrataGraft as Regenerative Medicine Advanced Therapy
6.3 Jul 13, 2017: MiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range
6.4 Jul 06, 2017: Lattice Biologics Announces Change in Director and Chairman of Scientific Advisory Board
6.5 Jul 05, 2017: MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down
6.6 Jul 04, 2017: Appointment of Angie Risley as Non-Executive Director and Chairman Elect of the Remuneration Committee
6.7 Jun 26, 2017: Lattice Biologics Announces Move to Belgrade, Montana
6.8 Jun 09, 2017: Acera Surgical appoints new board member
6.9 Jun 08, 2017: Amedica Releases 2016 Preliminary Earnings Report and Business Update
6.10 Jun 08, 2017: Amniox Medical Enters into Agreement with Intalere
6.11 Jun 07, 2017: Mallinckrodt Enrolls First Patient in Phase 3 Trial of StrataGraft Regenerative Skin Tissue
6.12 May 31, 2017: Lattice Biologics Appoints Chief Operating Officer
6.13 May 30, 2017: Lattice Biologics Reports Second Quarter 2017 Highlights
6.14 May 11, 2017: Biostage Reports 2017 First Quarter Financial Results and Provides Business Update
6.15 May 08, 2017: New Clinical Evidence Continues to Support the Effectiveness and Value of AMNIOX Medical Products
6.16 May 05, 2017: Smith & Nephew 2017 First Quarter Trading Report
6.17 May 04, 2017: MiMedx EpiFix Receives Coverage From Kaiser Permanente
6.18 May 04, 2017: First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft Regenerative Skin Tissue
6.19 May 04, 2017: Orthofix International Reports First Quarter 2017 Financial Results
6.20 May 03, 2017: Anika Reports First Quarter 2017 Financial Results
6.21 Apr 28, 2017: MiMedx Announces Record Results For First Quarter Of 2017
6.22 Apr 28, 2017: Kuros Biosciences Proposes Election of Four New Board Members
6.23 Apr 26, 2017: Kuros Biosciences Reports Financial Results for 2016
6.24 Apr 19, 2017: Amedica Announces Delayed Filing of Annual Report on Form 10-K and Receipt of Nasdaq Letter
6.25 Apr 18, 2017: Biostage Appoints Stephen F. Badylak DVM, PhD, MD, as Co-Chairman of Scientific Advisory Board
6.26 Apr 13, 2017: MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance
6.27 Apr 13, 2017: Kuros announces CEO succession
6.28 Apr 07, 2017: AMNIOX Highlights Three Studies Demonstrating Effectiveness of Umbilical Cord Tissue for Treating Chronic Wounds
6.29 Apr 06, 2017: Organogenesis Announces Presentation on Dermagraft at the 6th Stem Cell Product Development and Commercialization Conference
6.30 Apr 05, 2017: The Use Of MiMedx Allografts From The Company's Multiple Product Families To Be Presented At SAWC Conference
6.31 Mar 30, 2017: AMNIOX Study Confirms Benefits of CLARIX FLO for Plantar Fasciitis
6.32 Mar 23, 2017: Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
6.33 Mar 22, 2017: PolyMedics Innovations to Sell Kerecis Omega3-rich Fish-Skin Burn Treatment in the U.S.
6.34 Mar 19, 2017: MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors
6.35 Mar 09, 2017: Biostage Reports 2016 Financial Results and Provides Business Update
6.36 Mar 02, 2017: Lattice Biologics Reports First Quarter 2017 Highlights
6.37 Feb 27, 2017: Amedica Announces Results of Independent Femoral Head Wear Testing
6.38 Feb 27, 2017: Orthofix International Reports Fourth Quarter and Fiscal 2016 Financial Results
6.39 Feb 23, 2017: MiMedx Announces 2016 Record Results
6.40 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results
6.41 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011
6.42 Feb 09, 2017: Smith & Nephew Fourth Quarter Trading and Full Year 2016 Results
6.43 Feb 09, 2017: Smith & Nephew: Directorate Change
6.44 Jan 30, 2017: Lattice Biologics Reports Fourth Quarter and Year End 2016 Highlights
6.45 Jan 18, 2017: Orthofix Announces Resolution of SEC Investigations
6.46 Jan 12, 2017: Confirmation of CFO leaving Smith & Nephew
6.47 Jan 11, 2017: Shire PLC Subsidiaries to Pay $350 Million to Settle False Claims Act Allegations
6.48 Jan 10, 2017: DermACELL demonstrates superior clinical outcomes compared to AlloDerm in breast reconstruction
6.49 Jan 10, 2017: Orthofix Announces Preliminary 2016 Fourth Quarter and Full Year Net Sales Results
6.50 Jan 09, 2017: MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance
6.51 Dec 27, 2016: MiMedx EpiFix Receives Coverage From Aetna
6.52 Dec 20, 2016: Vivex Biomedical Receives Level II HCPCS Q-Code for Cygnus, a Human Amniotic Tissue Allograft
6.53 Dec 16, 2016: MiMedx 2017 Guidance Forecasts Revenue Growth In Excess Of 21% And Operating Earnings Growth In Excess Of 90%
6.54 Dec 14, 2016: MTF Wound Care's AmnioBand Receives the American Podiatric Medical Association Seal of Approval
6.55 Dec 14, 2016: MTF Wound Care's AlloPatch Pliable Receives the American Podiatric Medical Association Seal of Approval
6.56 Dec 13, 2016: Orthofix Announces Appointment of Alex Lukianov to Board of Directors
6.57 Nov 30, 2016: Graham Baker appointed Chief Financial Officer
6.58 Nov 22, 2016: Amedica appoints vice president of sales and marketing
6.59 Nov 22, 2016: Amedica Announces New Sales Leadership and Provides Regulatory Updates
6.60 Nov 10, 2016: Amedica Reports Third Quarter 2016 Financial Results
6.61 Nov 10, 2016: Biostage Reports 2016 Third Quarter Financial Results and Provides Business Update
6.62 Nov 10, 2016: Derma Sciences Reports 2016 Third Quarter Financial Results
6.63 Nov 03, 2016: Smith & Nephew Third Quarter 2016 Trading Report
6.64 Nov 03, 2016: MiMedx Announces USP-NF Monograph For dHACM Allografts Has Published
6.65 Oct 31, 2016: Orthofix International Reports Third Quarter 2016 Financial Results
6.66 Oct 27, 2016: MiMedx Announces Third Quarter 2016 Results
6.67 Oct 26, 2016: MNIOX Highlights Study Demonstrating Improved Outcomes in Patients Treated with CLARIX Regenerative Matrix as an Adjunct to Lumbar Discectomy
6.68 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results
6.69 Oct 19, 2016: Acelity Introduces ALLODERM SELECT DUO Regenerative Tissue Matrix
6.70 Oct 18, 2016: Kerecis Omega3-rich Fish-Skin Treatment for Wound Treatment to be Introduced to the Asian Market at a Major Medical Congress in Singapore
6.71 Oct 17, 2016: Admedus Vascucel Receives FDA Clearance For Launch In November
6.72 Oct 10, 2016: MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance
6.73 Oct 06, 2016: Amedica Provides Business Update
6.74 Oct 05, 2016: Tides Medical Showcasing New Product at SAWC
6.75 Oct 05, 2016: Amedica Announces Workforce Reduction
6.76 Sep 29, 2016: Kuros Biosciences Reports Financial Results for First Half-Year of 2016
6.77 Sep 19, 2016: Organogenesis Announces New Chief Financial Officer
6.78 Sep 16, 2016: Kerecis Wound-Treatment Product With Omega3 Fish Skin Now Eligible for Medicare Reimbursement in 45 States
6.79 Sep 14, 2016: TheraSkin Introduces a New 6 cm(2) Size
6.80 Sep 12, 2016: Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair
6.81 Sep 06, 2016: New Vendor Approval Gives Lattice Biologics Access to 39 Additional Hospitals
6.82 Sep 06, 2016: MiMedx Reaffirms Q3 and Full Year 2016 Guidance
6.83 Aug 30, 2016: MiMedx Provides Update On Clinical Trial With AmnioFix Injectable Product
6.84 Aug 30, 2016: MiMedx Provides Update On EpiFix BLA/PMA Compliant Chronic Wound Clinical Trial
6.85 Aug 29, 2016: MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix Technology
6.86 Aug 29, 2016: Lattice Biologics Reports Third Quarter 2016 Highlights
6.87 Aug 25, 2016: Admedus Set To Launch Vascular Product
6.88 Aug 25, 2016: AlloSource Supports NASA and Jet Propulsion Laboratory on Microbial Study
6.89 Aug 24, 2016: Derma Sciences’ AMNIOEXCEL Now Eligible for Reimbursement by Medicare Administrative Contractor NGS
6.90 Aug 22, 2016: MiMedx Amniotic Allografts Are Terminally Sterilized To Enhance Safety Related To Microbiological And Viral Transmission
6.91 Aug 19, 2016: Amedica Announces Receipt of Nasdaq Notice of Bid Price Deficiency
6.92 Aug 18, 2016: Derma Sciences Names Russell Olsen President of Advanced Wound Care
6.93 Aug 11, 2016: Biostage Reports 2016 Second Quarter Financial Results and Provides Business Update Outlining Key Near-term Milestones
6.94 Aug 09, 2016: Derma Sciences Reports 2016 Second Quarter Financial Results
6.95 Aug 01, 2016: Orthofix International Reports Second Quarter 2016 Financial Results
6.96 Aug 01, 2016: Lattice Biologics Gains Preferred Vendor Status With the Veterans Health Administration (VHA)

7. Appendix
7.1 Methodology
7.2 About
7.3 Contact Us
7.4 Disclaimer

1.1 List of Tables
Table 1: Tissue Engineered - Skin Substitutes - Pipeline Products by Stage of Development
Table 2: Tissue Engineered - Skin Substitutes - Pipeline Products by Segment
Table 3: Tissue Engineered - Skin Substitutes - Pipeline Products by Territory
Table 4: Tissue Engineered - Skin Substitutes - Pipeline Products by Regulatory Path
Table 5: Tissue Engineered - Skin Substitutes - Pipeline Products by Estimated Approval Date
Table 6: Tissue Engineered - Skin Substitutes - Ongoing Clinical Trials
Table 7: Tissue Engineered - Skin Substitutes Companies - Pipeline Products by Stage of Development
Table 8: Tissue Engineered - Skin Substitutes - Pipeline Products by Stage of Development
Table 9: Adept Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Plastic Surgery Graft - Product Status
Table 11: Plastic Surgery Graft - Product Description
Table 12: AGAM Biological Products Pipeline Products & Ongoing Clinical Trials Overview
Table 13: Skin Substitute - Product Status
Table 14: Skin Substitute - Product Description
Table 15: Agenta Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 16: Implantable Mesh - Tissue Support - Product Status
Table 17: Implantable Mesh - Tissue Support - Product Description
Table 18: Skin Graft - Post-Burns - Product Status
Table 19: Skin Graft - Post-Burns - Product Description
Table 20: Kerecis ehf Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Kerecis Omega3 Wound - Product Status
Table 22: Kerecis Omega3 Wound - Product Description
Table 23: Lattice Biologics Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 24: MarBrane - Product Status
Table 25: MarBrane - Product Description
Table 26: Skin + ECM - Product Status
Table 27: Skin + ECM - Product Description
Table 28: Mallinckrodt Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview
Table 29: ExpressGraft Antimicrobial - Diabetic Foot Ulcers - Product Status
Table 30: ExpressGraft Antimicrobial - Diabetic Foot Ulcers - Product Description
Table 31: ExpressGraftEnhance Tissue - Product Status
Table 32: ExpressGraftEnhance Tissue - Product Description
Table 33: StrataGraft - Diabetic Foot Ulcers - Product Status
Table 34: StrataGraft - Diabetic Foot Ulcers - Product Description
Table 35: StrataGraft - Epidermolysis Bullosa - Product Status
Table 36: StrataGraft - Epidermolysis Bullosa - Product Description
Table 37: StrataGraft - Scar Revision - Product Status
Table 38: StrataGraft - Scar Revision - Product Description
Table 39: StrataGraft - Scleroderma Digital Ulcers - Product Status
Table 40: StrataGraft - Scleroderma Digital Ulcers - Product Description
Table 41: StrataGraft - Severe Burns - Product Status
Table 42: StrataGraft - Severe Burns - Product Description
Table 43: StrataGraft - Venous Leg Ulcer - Product Status
Table 44: StrataGraft - Venous Leg Ulcer - Product Description
Table 45: Mallinckrodt Pharmaceuticals - Ongoing Clinical Trials Overview
Table 46: StrataGraft - Severe Burns - A Phase III Open-label, Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of Stratagraft Skin Tissue in Promoting Autologous Skin Tissue Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements and for Which Excision and Autografts Are Clinically Indicated
Table 47: StrataGraft - Severe Burns - Open-label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Single or Multiple Applications of StrataGraft Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects
Table 48: MiMedx Group Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 49: AmnioFix Injectable - Achilles Tendinitis - Product Status
Table 50: AmnioFix Injectable - Achilles Tendinitis - Product Description
Table 51: AmnioFix Injectable - Knee OA Pain - Product Status
Table 52: AmnioFix Injectable - Knee OA Pain - Product Description
Table 53: AmnioFix Injectable - Plantar Fasciitis - Product Status
Table 54: AmnioFix Injectable - Plantar Fasciitis - Product Description
Table 55: AmnioFix Injectable - Pressure Ulcer - Product Status
Table 56: AmnioFix Injectable - Pressure Ulcer - Product Description
Table 57: Organogenesis Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Dermagraft - Epidermolysis Bullosa - Product Status
Table 59: Dermagraft - Epidermolysis Bullosa - Product Description
Table 60: Dermagraft - Rotator Cuff Repair - Product Status
Table 61: Dermagraft - Rotator Cuff Repair - Product Description
Table 62: Dermagraft - Venous Leg Ulcers Repair - Product Status
Table 63: Dermagraft - Venous Leg Ulcers Repair - Product Description
Table 64: VCT01 - Product Status
Table 65: VCT01 - Product Description
Table 66: Smith & Nephew Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 67: KERAGRAF - Product Status
Table 68: KERAGRAF - Product Description
Table 69: Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Fibrin-PLGC Hybrid Scaffold - Product Status
Table 71: Fibrin-PLGC Hybrid Scaffold - Product Description
Table 72: Skin Graft Substitutes - Wound - Product Status
Table 73: Skin Graft Substitutes - Wound - Product Description
Table 74: Stratatech Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 75: ExpressGraft - Antineoplastic - Product Status
Table 76: ExpressGraft - Antineoplastic - Product Description
Table 77: ExpressGraft - Sclerotic Digital Ulcers - Product Status
Table 78: ExpressGraft - Sclerotic Digital Ulcers - Product Description
Table 79: ExpressGraft Antimicrobial - Venous Leg Ulcers - Product Status
Table 80: ExpressGraft Antimicrobial - Venous Leg Ulcers - Product Description
Table 81: ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers - Product Status
Table 82: ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers - Product Description
Table 83: ExpressGraft Pro-Angiogenic - Venous Leg Ulcers - Product Status
Table 84: ExpressGraft Pro-Angiogenic - Venous Leg Ulcers - Product Description
Table 85: Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview
Table 86: Artificial Skin Graft - Product Status
Table 87: Artificial Skin Graft - Product Description
Table 88: Tissue Regenix Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 89: dCELL - Small Diameter Graft - Product Status
Table 90: dCELL - Small Diameter Graft - Product Description
Table 91: dCELL Human Dermis - Chronic Wounds - Product Status
Table 92: dCELL Human Dermis - Chronic Wounds - Product Description
Table 93: dCELL Human Dermis - Plastic Surgery - Product Status
Table 94: dCELL Human Dermis - Plastic Surgery - Product Description
Table 95: Dermapure - Acute Wounds - Product Status
Table 96: Dermapure - Acute Wounds - Product Description
Table 97: Vericel Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 98: Epicel - Product Status
Table 99: Epicel - Product Description
Table 100: Worcester Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview
Table 101: Extracellular Matrix Scaffold - Product Status
Table 102: Extracellular Matrix Scaffold - Product Description
Table 103: Glossary

1.2 List of Figures
Figure 1: Tissue Engineered - Skin Substitutes - Pipeline Products by Stage of Development
Figure 2: Tissue Engineered - Skin Substitutes - Pipeline Products by Segment
Figure 3: Tissue Engineered - Skin Substitutes - Pipeline Products by Territory
Figure 4: Tissue Engineered - Skin Substitutes - Pipeline Products by Regulatory Path
Figure 5: Tissue Engineered - Skin Substitutes - Pipeline Products by Estimated Approval Date
Figure 6: Tissue Engineered - Skin Substitutes - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adept Medical Ltd
  • AGAM Biological Products
  • Agenta Biotechnologies Inc
  • Kerecis ehf
  • Lattice Biologics Ltd
  • Mallinckrodt Pharmaceuticals
  • MiMedx Group Inc
  • Organogenesis Inc
  • Smith & Nephew Plc
  • Sree Chitra Tirunal Institute for Med
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll